We were interested in assessing the repercussions of HER2 signaling inhibition on a panel of genes involved in breast cancer aggressiveness and metastasis (a full list of the genes and of the TLDA results is appended as Table S1). The gene discussed is ERBB2; the disease is breast carcinoma.